By Dr Matthew Lakelin PhD, TrakCel Co-Founder  

Introduction 

Three years ago, Radiopharma felt like a field on the brink of something bigger. The science was accelerating, interest from biopharma was rising, and investment was shifting steadily toward targeted radionuclide therapies. But despite that momentum, many operational challenges still looked eerily similar to what I saw a decade earlier: manual workarounds, racing against isotope decay, gaps in chain of custody, and coordination headaches that forced teams to operate in a constant state of urgency. 

Today, I can confidently say the landscape has changed. Not everywhere, not evenly, and not without growing pains. Radiopharma is stepping into a new phase defined by maturity, digital enablement, and operational discipline that finally matches the scientific sophistication behind these therapies. 

In this blog, I’ll share: 

• What has changed most dramatically in Radiopharma over the last three years

• Why advanced orchestration is no longer optional

• How platforms like OCELLOS are now solving problems that used to feel unsolvable

• What I believe is coming next for the industry

This perspective is shaped from the front lines: consulting with developers, manufacturers, and treatment centers, and in my role supporting customers across Radiopharma and advanced therapies. 

The Last Three Years: What’s Changed Most in Radiopharma 

1. Rising Complexity in Supply and Demand 

Three years ago, Radiopharma demand was climbing, but the supply chains weren’t ready for the influx of programs moving into late-stage clinical development. What we see now is far more complex: 

• More radionuclides 

• More personalized treatments 

• More sensitive time windows 

• More sites participating in manufacturing, QC testing, and administration 

The operational load has increased dramatically. What used to be a rare, specialized therapy category is now a rapidly scaling part of oncology pipelines. 

The challenge: greater volume doesn’t mix well with manual coordination, spreadsheets, or email chains. 

2. An Irreversible Shift Toward Patient-Specific Precision 

Radiopharmaceuticals have always been time-sensitive, but the precision required today is on a different level. We are no longer talking about broad windows. We are talking about: 

• Half-lives dictating hour-by-hour decisions 

• Dosing that must track back precisely to individual patients 

• Customized scheduling for each case 

• Real-time responses when something goes wrong using planned contingencies  

Three years ago, many organizations accepted a high rate of schedule slips, delivery failures, or product losses as “inevitable.” Today, that attitude is changing. Precision is not aspirational anymore. It’s expected. 

3. Stricter Global Regulatory Pressure 

Regulators have become far more assertive with Radiopharma operational compliance. In the last few years, scrutiny has increased around: 

• Documentation completeness 

• Chain of Identity requirements 

• Transport and custody validation 

• Proof that the right product reached the right patient exactly when intended 

Paper trails and pieced-together datasets simply don’t withstand audits anymore. The expectation is clear: full traceability from isotope to patient administration. 

4. A Migration Toward Digital Orchestration 

Five years ago, many developers still believed a Radiopharma-dedicated orchestration platform wasn’t necessary. They assumed their demand was too low or their workflows too “simple” to justify it. 

The last three years have decisively disproven that assumption. 

Today, most Radiopharma innovators we support are actively moving toward: 

• Centralized scheduling 

• Workflow orchestration 

• Digital chain of custody 

• Real-time tracking 

• Integrated communication across partners 

There is a recognition that scientific innovation has outpaced operational models. And the industry is finally correcting that imbalance. 

The New Problem Statement: Radiopharma Has Outgrown Manual Processes 

Here’s the truth: Radiopharma has become too fast, too regulated, too precise, and too interconnected to run manually. 

When the timing is dictated by half-lives, every hour counts. 

When the product is personalized, every handoff matters. 

When the therapy is expensive, every delay becomes costly. 

But more importantly, every therapy connects directly to a patient who cannot afford operational uncertainty. 

This is why digital orchestration is no longer an enhancement. It’s a requirement. 

Why TrakCel Has a Focus on Radiopharma 

I’ve observed that many technology companies misunderstand Radiopharma. They underestimate the time pressure or try to force-fit generic supply chain solutions into spaces where they simply don’t work. 

As I’ve collaborated with the TrakCel team to refine solutions for Radiopharma, I’ve had many conversations with my colleague Dr Akshay Peer, TrakCel’s Chief Product Officer, about the operational challenges that continue to intensify across the industry. He has seen the same shift taking place among the therapy developers and clinical networks he supports: 

“Radiopharma workflows have become far more complex, yet many teams are still relying on systems that were never designed for time-critical, patient-specific therapies. The science has moved forward quickly, and the supporting digital infrastructure needs to advance with it.” 
– Dr. Akshay Peer, Chief Product Officer, TrakCel 

TrakCel’s experience comes from cell and gene therapy, a domain where timing, traceability, and patient-specific workflows are mission-critical. Three years ago, we began adapting that expertise for Radiopharma. Today, TrakCel’s OCELLOS platform has shown itself to be one of the first solutions that actually aligns with the operational realities Radiopharma teams face every day. 

How OCELLOS Supports Modern Radiopharma Workflows 

1. Just-in-Time Workflow Management 

Radiopharma lives on razor-thin time margins. OCELLOS supports: 

• Precise coordination of production and shipment 

• Real-time visibility of every step 

• Automated prompts when actions need to occur 

In manual workflows, timing is always at risk. In OCELLOS, timing becomes predictable. 

2. Real-Time Tracking and Alerts 

When a therapy is in motion, I want everyone involved to know: 

• Where it is 

• Who is responsible 

• Whether it is on schedule 

• Whether an action is overdue 

OCELLOS gives that visibility. And when something goes wrong, the system triggers alerts that go directly to the responsible party, not a distribution list where accountability gets lost. 

3. Chain of Custody and Chain of Identity Built In 

Radiopharma therapy is patient-specific. There can be no uncertainty about: 

• Who produced the dose 

• Who handled it 

• How it moved 

• Where it is now 

• Who received it 

OCELLOS captures every step automatically in a validated, audit-ready format. This removes the risk inherent in manual documentation. 

4. Integrated Communication During Delays 

One of Radiopharma’s toughest operational realities is that delays happen. A traffic incident, a courier handoff issue, or a late QC release can quickly erode the therapy’s remaining viability. 

OCELLOS reduces the impact of delays by immediately pinpointing: 

• The drug product’s custodian 

• The next required action 

• The right contact to notify 

This level of rapid response used to be impossible. Now it’s standard. 

5. Customizable Workflows for Therapy-Specific Needs 

Radiopharma is diverse. Isotopes differ. Manufacturing models differ. Clinic workflows differ. 

OCELLOS doesn’t force uniformity. It supports: 

• Therapy-specific branching processes 

• Custom timing rules 

• Site-specific configurations 

This is crucial in an industry where no two therapy programs operate the same way. 

The Business-Level Impact I’ve Seen 

Enhanced Compliance Without Additional Burden 

Teams used to spend enormous time assembling documentation for inspections. OCELLOS automates this and provides: 

• Complete audit trails 

• Standardized data capture 

• A single accurate source of truth 

In a globally regulated environment, this is no longer optional. 

Improved Operational Efficiency 

By reducing manual calls, emails, spreadsheets, and rework, teams finally have room to focus on patient care and operational strategy. 

I’ve seen: 

• Fewer errors 

• Faster scheduling 

• Improved coordination between manufacturers and clinics 

• A significant reduction in time spent managing drug product supply  

• Dramatic reduction in product loss 

All of this translates into fewer operational fires and more predictable days. 

Accelerated Time-to-Treatment 

This is the most meaningful impact. When workflows run smoothly, patients receive treatments faster. And in oncology, speed is not a convenience. It’s part of the therapy’s clinical impact. 

OCELLOS supports this by: 

• Optimizing logistics 

• Reducing dwell times 

• Ensuring timely handoffs 

• Shortening communication loops 

Scalability for the Next Wave of Therapies 

One of the biggest mistakes companies make is planning for today instead of where they’ll be in two years. OCELLOS is built to grow with organizations, not bottleneck them. 

Whether a company is managing: 

• A single therapy 

• Multiple isotopes 

• Global expansion 

OCELLOS scales without forcing teams into new systems or expensive rebuilds. 

What the Last Three Years Mean for the Next Three 

Based on my experience helping organizations deploy orchestration systems, here are the trends I believe will define Radiopharma’s near future. 

1. More Patient-Specific Therapies With Narrower Time Windows 

Customization will increase, not decrease. That means workflows will only get more complex. Digital orchestration will become standard from day one of development. 

2. Multi-Site Manufacturing Will Become Normal 

To meet global demand, programs will rely on distributed manufacturing networks. Manual coordination will crumble under this model unless replaced by real-time orchestration. 

3. Supply Records Will Come Under Greater Scrutiny During Audits 

Regulators will expect richer documentation, automated timestamping, and tighter chain-of-identity controls. Platforms like OCELLOS position organizations to meet these expectations without straining their teams. 

4. Capacity Constraints Will Drive Innovation in Scheduling and Logistics 

Facilities will need smarter, automated scheduling tools to avoid bottlenecks and maximize throughput. Manual scheduling simply cannot do this at scale. 

5. More Therapies Will Integrate with Broader Digital Ecosystems 

Radiopharma will not be isolated. It will connect with: 

• EHR systems 

• Courier networks 

• Manufacturing execution systems 

• Clinical scheduling systems 

OCELLOS is already designed to operate in these interconnected environments. 

Closing Thoughts 

Radiopharma has changed more in the past three years than in the decade before it. And while the scientific progress is exciting, the operational evolution is just as essential. Without strong orchestration, even the best therapies struggle to reach patients reliably. 

In my recent conversations with Ravi Nalliah, TrakCel’s CEO, he highlighted why product vision, interoperability, and scalability must now sit at the center of Radiopharma’s digital transformation: 

“To support the next generation of Radiopharma therapies, our products must deliver more than workflow management. They need to integrate seamlessly across complex technology ecosystems, connect every stakeholder with real‑time clarity, and scale as programs expand globally. Interoperability and scalability are no longer aspirations; they are foundational requirements for delivering these therapies safely and consistently.” 

– Ravi Nalliah, Chief Executive Officer, TrakCel 

What I’ve seen in my work with TrakCel is that Radiopharma finally has access to the kind of digital infrastructure that Cell and Gene Therapy has relied on for years. The industry is stepping into a new era of precision, reliability, and scalability. And patients will ultimately benefit most from that shift. 

If you’re looking to strengthen your Radiopharma operations, streamline your workflows, or prepare for future scaling, I encourage you to explore what OCELLOS can offer. As someone who has spent years navigating the complexities of this field, I can say with confidence that the industry has never been more ready for this kind of transformation.